Publication of First Results in Ongoing Malaria Vaccine Trial Marks Important Milestone
Initial results from ongoing Phase 3 efficacy trial show that the RTS,S malaria vaccine candidate reduces malaria by half in African children 5–17 months old, after 12 months of follow-up. Read more »
Partnering with us
We are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.
Our portfolio
We maintain a diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.
What we do and how we do it
We provide funding and technical support to partners worldwide to accelerate the development of malaria vaccines. We also work to ensure that malaria vaccines will reach those who need them.




